Medtronic (NYSE:MDT) said today it launched a new clinical trial evaluating the use of its ECG belt research system as a diagnostic tool for improving cardiac resynchronization therapy for heart failure patients. The Fridley, Minn.-based company said it has enrolled the first patients in the trial at Des Moines, Iowa’s Mercy Medical Center – West Lakes […]
Pulmatrix touts data from first-in-human trial of inhaled anti-fungal therapy
Pulmatrix (NSDQ:PULM) said today that all dosing and follow-up visits have finished for its first-in-human study of an inhaled formulation of itraconazole as a treatment of allergic bronchopulmonary aspergillosis in people with asthma. The inhaled iSperse formulation, called Pulmazole, was well-tolerated, according to the Lexington, Mass.-based company. Pulmatrix plans to launch a Phase II trial of […]
RenovoRx sets its sights on localized treatment of pancreatic cancer
People living with pancreatic cancer find themselves facing devastating odds – the five-year survival rate is in the single digits, according to the American Cancer Rate. Pursuing treatment often means dealing with the side effects of systemic chemotherapy, including hair loss, fatigue and neuropathy. Shaun Bagai and his team at RenovoRx think that their catheter could help […]
Sanuwave Health, HyperMed partner for DermaPace diabetic foot ulcer study
Sanuwave Health (OTC:SNWV) said yesterday it is partnering with HyperMed to sponsor a clinical investigation exploring Sanuwave’s DermaPace system designed for treating diabetic foot ulcers. The joint study will look to quantify the level of increased perfusion and oxygenation during and after treatment with the DermaPace, Suwanee, Ga.-based Sanuwave said. The study will use HyperMed’s Hyperview […]
Oyster Point takes aim at the root of dry eye disease with intranasal drug-delivery technique
Large pharmaceutical companies dominate the dry eye disease space – Allergan (NYSE:AGN) rakes in more than a billion dollars every year for its Restasis eye drops. Eight-person Oyster Point Pharma wants in on that market. But it’s betting on a completely different approach. “What we’ve come up with is a very innovative nasal spray, which when sprayed into the […]
Cingulate raises $7.5m for controlled-release ADHD therapy
Cingulate Therapeutics said today that it landed a $7.5 million investment to help fund the development of its controlled-release ADHD drugs. The Kansas City-based company is working on a set of therapies that utilize its ‘Precision Time Release’ drug-delivery platform. Cingulate’s CEO, Shane Schaffer, told Drug Delivery Business News that his company set out to create an ADHD therapy that tackles all […]
Medtronic touts one-year data from insulin pump study
Medtronic (NYSE:MDT) and UnitedHealthcare (NYSE:UNH) today touted first-year results from a 6,000-person analysis designed to compare hospital admission rates between people with diabetes using insulin pumps and people controlling their diabetes with multiple daily injections of insulin. The study included people using Medtronic’s MiniMed 630G system, as well as previous iterations of the medtech giant’s insulin pumps. Get […]
Vaccine maker PaxVax tackles the unmet need posed by chikungunya virus
Transmitted by the same mosquitoes that spread Zika virus and dengue fever, the chikungunya virus is named for an African word meaning “to become contorted.” People infected with the alphavirus are afflicted with lasting joint pain that causes their backs to hunch over, according to the World Health Organization. The virus, which has cropped up in […]
Siga Technologies touts pivotal data for oral smallpox therapy
Siga Technologies (NSDQ:SIGA) said today that data from a pivotal human safety study and animal efficacy studies of its oral smallpox therapy were published in the New England Journal of Medicine. Data from the studies support the efficacy and favorable safety profile of Tpoxx, an oral formulation of tecovirimat. Get the full story at our sister site, […]
FDA approves ReCor Medical’s pivotal ultrasound denervation study
ReCor Medical said this week that the FDA approved a new pivotal study of the company’s Paradise ultrasound denervation system for the treatment of hypertension. The Palo Alto, Calif.-based company reported that its trial, Radiance-II, will be a randomized, sham-controlled study in patients with moderate hypertension. The study is designed to demonstrate the Paradise system’s […]
Ocugen launches Ph3 trial for eye disease nanoemulsion
Ocugen said today that it launched the first of two pivotal Phase III trials for its OCU300 nanoemulsion designed to treat the symptoms of ocular graft versus host disease. The Malvern, Penn.-based company’s drug is a nanoemulsion formulation of brimonidine tartrate made using Ocugen’s OcuNanoE technology. Get the full story at our sister site, Drug Delivery […]
- 1
- 2
- 3
- …
- 139
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+